OR WAIT null SECS
Bangalore, India-May 6, 2009
-Novotech, a leading Australia based clinical research company, today announced it had entered into a strategic venture with ETI Klinical Pvt Ltd, part of the Karle Group of companies, a US $ 600 million Indian multinational.
The joint venture designed to service the growing demand for global clinical research in the region will operate across India and offer full clinical and data management services.
Novotech CEO Alek Safarian said the joint venture will leverage the huge opportunities in the growing Indian clinical research sector and drive more global studies to the country.
The two companies have extensive experience managing FDA clinical research and will collaborate to service both regional and international pharma and biotech firms.
Karle Group CEO Mr Mahendra Karle said that with the joint venture clients could access the company’s extensive reach across India which included Memorandum of Understanding with 92 prequalified sites with proven recruitment capability and compliance, providing access to over 5 million patients and 13,000 beds.
Therapeutic areas include oncology, gastroenterology, urology, nephrology, ophthalmology, cardiology, diabetology, dermatology, orthopedics, postoperative pain, neurology, otorhinolaryngology, infectious diseases, respiratory diseases, endocrinology, psychiatry, geriatrics, hematology, metabolic disorders devices and vaccines.
“We approached Novotech because of its proven reputation in the region, its focus on Australasia, and its global business development reach and client network.” said Mr. Mahendra Karle.
The joint venture data management services include Oracle Clinical and SAS, and Novotech's Clintrial giving maximum flexibility to clients.
Safarian said ETI offers an exceptional mix of high-quality clinical research services, real-time data acquisition and personalized communication processes to manage a clinical trial from initial planning to approval, on time and on budget.
“We share a similar business culture and approach to high-quality and time critical clinical trials and research, serving the pharmaceutical, biotechnology, and medical device industries,” said Safarian.
Headquartered in Sydney, Novotech is focused on the Australasian region but has worldwide reach through the company's network of strategic partners. As the largest independent CRO in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region.
In the past year, Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, has expanded rapidly into Asia bringing its global reputation for high quality service and regional expertise to this growth area.
Novotech has been recognized as
Australia’s leading CRO
by Frost & Sullivan for the past two years.
About ETI Karle Clinical Pvt
ETI Karle Clinical Pvt. Ltd belongs to the Karle Group of Companies, a US $ 600 million Indian Multinational. ETI offers an exceptional mix of high-quality clinical research services, real-time data acquisition and personalized communication processes to manage a clinical trial from initial planning to approval, on time and on budget, every time.
We consider it our creed to conduct multi-specialty clinical trials in a high-quality, confidential and prompt fashion consistent with 'Good Clinical Practice' guiding principles and with scrupulous attention to Quality Solutions that will exceed your expectations. The involvement of our management does not stop when the contract is signed. And our senior managers are available to you 24x7, helping you with very rapid decision-making said Dr M.V.Nagendran.